Ariad Reaches New 52-Week High (ARIA)

NEW YORK ( TheStreet) -- Ariad Pharmaceuticals (Nasdaq: ARIA) hit a new 52-week high Friday as it is currently trading at $16.83, above its previous 52-week high of $16.75 with 1.4 million shares traded as of 11:15 a.m. ET. Average volume has been 3.4 million shares over the past 30 days.

Ariad has a market cap of $2.59 billion and is part of the health care sector and drugs industry. Shares are up 34.9% year to date as of the close of trading on Thursday.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients.

TheStreet Ratings rates Ariad as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. You can view the full Ariad Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Emerging Markets Get Pounded by Trade War Concerns

Emerging Markets Get Pounded by Trade War Concerns

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns

PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug

PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug

Tesla Slumps After Mary McCormack Tweets Husband's Flaming Model S

Tesla Slumps After Mary McCormack Tweets Husband's Flaming Model S

Stocks Dive Globally as U.S.-China Trade War Intensifies

Stocks Dive Globally as U.S.-China Trade War Intensifies